384 related articles for article (PubMed ID: 16401690)
1. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis.
Kühbacher T; Ott SJ; Helwig U; Mimura T; Rizzello F; Kleessen B; Gionchetti P; Blaut M; Campieri M; Fölsch UR; Kamm MA; Schreiber S
Gut; 2006 Jun; 55(6):833-41. PubMed ID: 16401690
[TBL] [Abstract][Full Text] [Related]
2. High-dose probiotics for the treatment of active pouchitis.
Gionchetti P; Rizzello F; Morselli C; Poggioli G; Tambasco R; Calabrese C; Brigidi P; Vitali B; Straforini G; Campieri M
Dis Colon Rectum; 2007 Dec; 50(12):2075-82; discussion 2082-4. PubMed ID: 17934776
[TBL] [Abstract][Full Text] [Related]
3. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
Miele E; Pascarella F; Giannetti E; Quaglietta L; Baldassano RN; Staiano A
Am J Gastroenterol; 2009 Feb; 104(2):437-43. PubMed ID: 19174792
[TBL] [Abstract][Full Text] [Related]
4. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice.
Shen B; Brzezinski A; Fazio VW; Remzi FH; Achkar JP; Bennett AE; Sherman K; Lashner BA
Aliment Pharmacol Ther; 2005 Oct; 22(8):721-8. PubMed ID: 16197493
[TBL] [Abstract][Full Text] [Related]
5. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.
Gionchetti P; Rizzello F; Venturi A; Brigidi P; Matteuzzi D; Bazzocchi G; Poggioli G; Miglioli M; Campieri M
Gastroenterology; 2000 Aug; 119(2):305-9. PubMed ID: 10930365
[TBL] [Abstract][Full Text] [Related]
6. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells.
Caballero-Franco C; Keller K; De Simone C; Chadee K
Am J Physiol Gastrointest Liver Physiol; 2007 Jan; 292(1):G315-22. PubMed ID: 16973917
[TBL] [Abstract][Full Text] [Related]
7. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.
Singh S; Stroud AM; Holubar SD; Sandborn WJ; Pardi DS
Cochrane Database Syst Rev; 2015 Nov; (11):CD001176. PubMed ID: 26593456
[TBL] [Abstract][Full Text] [Related]
8. VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases.
Chapman TM; Plosker GL; Figgitt DP
Drugs; 2006; 66(10):1371-87. PubMed ID: 16903771
[TBL] [Abstract][Full Text] [Related]
9. Specific detection of bifidobacterium strains in a pharmaceutical probiotic product and in human feces by polymerase chain reaction.
Brigidi P; Vitali B; Swennen E; Altomare L; Rossi M; Matteuzzi D
Syst Appl Microbiol; 2000 Oct; 23(3):391-9. PubMed ID: 11108019
[TBL] [Abstract][Full Text] [Related]
10. Fungi and inflammatory bowel diseases: Alterations of composition and diversity.
Ott SJ; Kühbacher T; Musfeldt M; Rosenstiel P; Hellmig S; Rehman A; Drews O; Weichert W; Timmis KN; Schreiber S
Scand J Gastroenterol; 2008; 43(7):831-41. PubMed ID: 18584522
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic potential of antibiotics and probiotics in the treatment of pouchitis.
Gionchetti P; Calabrese C; Lauri A; Rizzello F
Expert Rev Gastroenterol Hepatol; 2015; 9(9):1175-81. PubMed ID: 26202437
[TBL] [Abstract][Full Text] [Related]
12. Assessment of mucosal inflammation and blood flow in response to four weeks' intervention with probiotics in patients operated with a J-configurated ileal-pouch-anal-anastomosis (IPAA).
Laake KO; Line PD; Grzyb K; Aamodt G; Aabakken L; Røset A; Hvinden AB; Bakka A; Eide J; Bjørneklett A; Vatn MH
Scand J Gastroenterol; 2004 Dec; 39(12):1228-35. PubMed ID: 15743000
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases.
Chapman TM; Plosker GL; Figgitt DP
BioDrugs; 2007; 21(1):61-3. PubMed ID: 17263590
[TBL] [Abstract][Full Text] [Related]
14. Change in the bacterial flora of pouchitis.
Iwaya A; Iiai T; Okamoto H; Ajioka Y; Yamamoto T; Asahara T; Nomoto K; Hatakeyama K
Hepatogastroenterology; 2006; 53(67):55-9. PubMed ID: 16506376
[TBL] [Abstract][Full Text] [Related]
15. [Probiotics in chronic inflammatory bowel disease].
Böhm S; Kruis W
MMW Fortschr Med; 2006 Aug; 148(35-36):30-4. PubMed ID: 16995360
[TBL] [Abstract][Full Text] [Related]
16. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells.
Pronio A; Montesani C; Butteroni C; Vecchione S; Mumolo G; Vestri A; Vitolo D; Boirivant M
Inflamm Bowel Dis; 2008 May; 14(5):662-8. PubMed ID: 18240282
[TBL] [Abstract][Full Text] [Related]
17. [Probiotics--should we change the treatment strategy for pouchitis?].
Klinge LG; Kjeldsen J
Ugeskr Laeger; 2006 Oct; 168(41):3516-8. PubMed ID: 17059804
[TBL] [Abstract][Full Text] [Related]
18. The effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis.
Persborn M; Gerritsen J; Wallon C; Carlsson A; Akkermans LM; Söderholm JD
Aliment Pharmacol Ther; 2013 Oct; 38(7):772-83. PubMed ID: 23957603
[TBL] [Abstract][Full Text] [Related]
19. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial.
Gionchetti P; Rizzello F; Helwig U; Venturi A; Lammers KM; Brigidi P; Vitali B; Poggioli G; Miglioli M; Campieri M
Gastroenterology; 2003 May; 124(5):1202-9. PubMed ID: 12730861
[TBL] [Abstract][Full Text] [Related]
20. An assessment of bacterial dysbiosis in pouchitis using terminal restriction fragment length polymorphisms of 16S ribosomal DNA from pouch effluent microbiota.
Lim M; Adams JD; Wilcox M; Finan P; Sagar P; Burke D
Dis Colon Rectum; 2009 Aug; 52(8):1492-500. PubMed ID: 19617766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
